23andMe entered the scene by collecting saliva samples from millions of customers and providing ancestry results. However, the company aimed to expand its services to develop new medicines and offer personalized healthcare. It hoped its vast genetic data would aid research.
Despite this goal, 23andMe struggled. The company’s efforts to become a biotechnology firm and health-care provider stalled. Its failure highlights the challenges of translating DNA data into tangible benefits for medicine and care.
Source: https://www.washingtonpost.com/technology/2025/03/25/23andme-collapse-dna-data